Search our team at AdventHealth Research Institute
-
NCT03213678
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors
This study is not currently enrolling.Associated Conditions: Cancer, Multiple Tumor TypesResearch Area: Pediatrics ResearchResearch Location: Orlando, FloridaThis is a Phase 2 study of a drug called LY3023414. In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer.
-
NCT04284774
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations
This study is not currently enrolling.Associated Conditions: Cancer, Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThis is a Phase 2 study of a study drug called tipifarnib. The main goal of the study is to find out what effect, good and/or bad effects the study drug tipifarnib may have on your tumor. A second...
-
NCT04195555
APEC1621K NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations.
This study is not currently enrolling.Associated Conditions: Cancer, Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Orlando, FloridaThe main goal is to find out what effect, good and/or bad effects AG-120 (ivosidenib) on your tumor. A second goal of the study is to evaluate side effects that might be caused by AG-120 (ivosidenib)...
-
NCT03526250
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
This study is not currently enrolling.Associated Conditions: Cancer, Multiple Tumor TypesResearch Area: Pediatrics ResearchThe main goal of this study is to test any good and bad effects of the palbociclib on your tumor. A second goal of the study is to evaluate side effects that might be caused by palbociclib.
-
NCT03698994
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (ulixertinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations
This study is not currently enrolling.Associated Conditions: Cancer, Multiple Tumor TypesResearch Area: Pediatrics ResearchYou are being asked to take part in this research study because your tumor results from the NCI-COG Pediatric MATCH screening protocol make you a candidate to receive the study drug called BVD-523FB...
-
NCT05194072
A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer Research -
NCT05614739
AN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Celebration, FloridaAN OPEN-LABEL, MULTICENTER STUDY OF LOXO-435 (LY3866288) IN ADVANCED SOLID TUMOR MALIGNANCIES WITH FGFR3 ALTERATIONS
-
NCT06285097
A Phase 1 Dose Escalation and Expansion Study To Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Antitumor Activity Of PF-07820435 as Monotherapy and In Combination in Participants With Advanced Solid Tumors
This study is not currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchStudy To Evaluate Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, And Antitumor Activity Of PF-07820435 As Monotherapy And In Combination In Participants With Advanced Solid Tumors
-
NCT05176483
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (STELLAR-002)
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Celebration, FloridaYou are being asked to take part in a clinical research study called STELLAR-002 because you have been diagnosed with cancer or your cancer has worsened since your last treatment. If you join this...
-
NCT04140526
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open-label Phase IA/IB Study.
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThis is a research study to find out if an experimental drug called ONC-392 is safe and effective in cancer patients and how the drug is absorbed and processed in the body of patients with cancer. ONC...
-
NCT05457556
A Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) versus HLA-Haploidentical Related (Haplo) Myeloablative Hematopoietic Cell Transplantation for Children, Adolescents, and Young Adults (AYA) with Acute Leukemia or Myelodysplastic Syndrome (MDS)
This study is currently enrolling.Associated Conditions: Cancer, Multiple Tumor TypesResearch Area: Pediatrics ResearchResearch Location: Orlando, FloridaYou are being asked to take part in this research study because you have been diagnosed with acute leukemia or myelodysplastic syndrome (MDS).
-
NCT06026410
KO-2806-001: Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients with Advanced Solid Tumors
This study is currently enrolling.Associated Conditions: Multiple Tumor TypesResearch Area: Cancer ResearchResearch Location: Celebration, FloridaThe purposes of this study are to:
• Determine the highest tolerable dose of KO-2806 given orally (by mouth) in combination with cabozantinib.
• Determine whether KO-2806 has an antitumor effect...